123 related articles for article (PubMed ID: 22243807)
1. Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain.
Niles LP; Sathiyapalan A; Bahna S; Kang NH; Pan Y
Int J Neuropsychopharmacol; 2012 Oct; 15(9):1343-50. PubMed ID: 22243807
[TBL] [Abstract][Full Text] [Related]
2. Regional upregulation of hippocampal melatonin MT2 receptors by valproic acid: therapeutic implications for Alzheimer's disease.
Bahna SG; Sathiyapalan A; Foster JA; Niles LP
Neurosci Lett; 2014 Jul; 576():84-7. PubMed ID: 24909617
[TBL] [Abstract][Full Text] [Related]
3. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells.
Castro LM; Gallant M; Niles LP
J Neurochem; 2005 Dec; 95(5):1227-36. PubMed ID: 16313512
[TBL] [Abstract][Full Text] [Related]
4. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation.
Jawed S; Kim B; Ottenhof T; Brown GM; Werstiuk ES; Niles LP
Eur J Pharmacol; 2007 Mar; 560(1):17-22. PubMed ID: 17303109
[TBL] [Abstract][Full Text] [Related]
5. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers.
Niles LP; Armstrong KJ; Rincón Castro LM; Dao CV; Sharma R; McMillan CR; Doering LC; Kirkham DL
BMC Neurosci; 2004 Oct; 5():41. PubMed ID: 15511288
[TBL] [Abstract][Full Text] [Related]
6. Induction of neurotrophic and differentiation factors in neural stem cells by valproic acid.
Almutawaa W; Kang NH; Pan Y; Niles LP
Basic Clin Pharmacol Toxicol; 2014 Aug; 115(2):216-21. PubMed ID: 24460582
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic induction of melatonin MT
Bahna SG; Niles LP
Eur Neuropsychopharmacol; 2017 Aug; 27(8):828-832. PubMed ID: 28648552
[TBL] [Abstract][Full Text] [Related]
8. Brain injury results in lower levels of melatonin receptors subtypes MT1 and MT2.
Osier ND; Pham L; Pugh BJ; Puccio A; Ren D; Conley YP; Alexander S; Dixon CE
Neurosci Lett; 2017 May; 650():18-24. PubMed ID: 28377323
[TBL] [Abstract][Full Text] [Related]
9. Anatomical and cellular localization of melatonin MT1 and MT2 receptors in the adult rat brain.
Lacoste B; Angeloni D; Dominguez-Lopez S; Calderoni S; Mauro A; Fraschini F; Descarries L; Gobbi G
J Pineal Res; 2015 May; 58(4):397-417. PubMed ID: 25726952
[TBL] [Abstract][Full Text] [Related]
10. Altered MT1 and MT2 melatonin receptors expression in the hippocampus of pilocarpine-induced epileptic rats.
Rocha AKAA; de Lima E; Amaral F; Peres R; Cipolla-Neto J; Amado D
Epilepsy Behav; 2017 Jun; 71(Pt A):23-34. PubMed ID: 28460319
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine upregulates melatonin MT
Hartung EE; Mukhtar SZ; Shah SM; Niles LP
Mol Biol Rep; 2020 Jun; 47(6):4867-4873. PubMed ID: 32410138
[TBL] [Abstract][Full Text] [Related]
12. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments.
Tang YP; Ma YL; Chao CC; Chen KY; Lee EH
J Neurosci Res; 1998 Sep; 53(5):593-604. PubMed ID: 9726430
[TBL] [Abstract][Full Text] [Related]
13. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
[TBL] [Abstract][Full Text] [Related]
14. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Sharma R; McMillan CR; Tenn CC; Niles LP
Brain Res; 2006 Jan; 1068(1):230-6. PubMed ID: 16375867
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of melatonin receptors in neuropsychiatric disorders.
Bahna SG; Niles LP
Br J Pharmacol; 2018 Aug; 175(16):3209-3219. PubMed ID: 28967098
[TBL] [Abstract][Full Text] [Related]
16. Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line.
Watanabe M; Kobayashi Y; Takahashi N; Kiguchi K; Ishizuka B
J Obstet Gynaecol Res; 2008 Aug; 34(4):567-73. PubMed ID: 18937711
[TBL] [Abstract][Full Text] [Related]
17. Neu-P11, a novel MT1/MT2 agonist, reverses diabetes by suppressing the hypothalamic-pituitary-adrenal axis in rats.
Zhou J; Zhang J; Luo X; Li M; Yue Y; Laudon M; Jia Z; Zhang R
Eur J Pharmacol; 2017 Oct; 812():225-233. PubMed ID: 28687198
[TBL] [Abstract][Full Text] [Related]
18. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies.
Juszczak M; Roszczyk M; Kowalczyk E; Stempniak B
J Physiol Pharmacol; 2014 Dec; 65(6):777-84. PubMed ID: 25554981
[TBL] [Abstract][Full Text] [Related]
19. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal 'clock' gene expression in striatal neurons in vitro.
Imbesi M; Arslan AD; Yildiz S; Sharma R; Gavin D; Tun N; Manev H; Uz T
J Pineal Res; 2009 Jan; 46(1):87-94. PubMed ID: 18798788
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of melatonin membrane receptors increases calcium-binding proteins and protects VSC4.1 motoneurons from glutamate toxicity through multiple mechanisms.
Das A; Wallace G; Reiter RJ; Varma AK; Ray SK; Banik NL
J Pineal Res; 2013 Jan; 54(1):58-68. PubMed ID: 22823500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
